PDS Biotechnology Corporation (PDSB): Price and Financial Metrics
PDSB Price/Volume Stats
| Current price | $3.22 | 52-week high | $10.27 |
| Prev. close | $2.99 | 52-week low | $2.59 |
| Day low | $2.99 | Volume | 681,902 |
| Day high | $3.24 | Avg. volume | 878,830 |
| 50-day MA | $4.55 | Dividend yield | N/A |
| 200-day MA | $5.04 | Market Cap | 118.11M |
PDSB Stock Price Chart Interactive Chart >
PDS Biotechnology Corporation (PDSB) Company Bio
PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc. Following the merger, Edge will operate as “PDS Biotechnology Corporation” and the stock will trade on the Nasdaq Capital Market beginning on March 18, 2019 under the ticker symbol \
Latest PDSB News From Around the Web
Below are the latest news stories about PDS BIOTECHNOLOGY CORP that investors may wish to consider to help them evaluate PDSB as an investment opportunity.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducemen |
PDS Biotech Appoints Lars Boesgaard as Chief Financial OfficerPRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned as |
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to the PDS Biotechnology Third Quarter 2023 Earnings Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions]. As a reminder, this conference is being recorded. I’d now like to turn the conference over […] |
PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ...Research and Development Expenses Rise as PDSB Advances its Immunotherapy Pipeline |
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business UpdateAnnounced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1Announced 2-year overall survival rate of 74% in VERSATILE-002 Phase 2 trial of ICI-naïve HPV16-positive recurrent or metastatic head and neck cancer patients; published 2-year overall survival of less than 30% with FDA approved ICI1Announced interim safety and immune response dat |
PDSB Price Returns
| 1-mo | -30.30% |
| 3-mo | -34.69% |
| 6-mo | -18.48% |
| 1-year | -49.13% |
| 3-year | -43.31% |
| 5-year | -49.29% |
| YTD | -35.21% |
| 2023 | -62.35% |
| 2022 | 62.96% |
| 2021 | 278.50% |
| 2020 | -19.25% |
| 2019 | -58.72% |
Loading social stream, please wait...